Achilles Therapeutics PLC (ACHL)
0.93
+0.01
(+1.63%)
USD |
NASDAQ |
May 17, 16:00
0.93
0.00 (0.00%)
After-Hours: 20:00
Achilles Therapeutics Shareholders Equity (Quarterly): 130.35M for March 31, 2024
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 130.35M |
| December 31, 2023 | 142.37M |
| September 30, 2023 | 153.48M |
| June 30, 2023 | 173.84M |
| March 31, 2023 | 185.17M |
| December 31, 2022 | 197.04M |
| September 30, 2022 | 202.62M |
| Date | Value |
|---|---|
| June 30, 2022 | 231.59M |
| March 31, 2022 | 266.46M |
| December 31, 2021 | 289.53M |
| September 30, 2021 | 305.11M |
| June 30, 2021 | 323.97M |
| March 31, 2021 | 179.05M |
| December 31, 2020 | 189.37M |
Shareholders' Equity Definition
Shareholder's Equity is a main portion of the balance sheet of a company that measures the net value of a company. The reason for this is because the from an accounting perspective, the balance sheet equation is Shareholder's Equity = Assets - Liabilities. A few examples of shareholder's equity of a company include retained earnings, paid in capital, and preferred stock.
Shareholders Equity (Quarterly) Range, Past 5 Years
130.35M
Minimum
Mar 2024
323.97M
Maximum
Jun 2021
212.14M
Average
193.21M
Median
Shareholders Equity (Quarterly) Benchmarks
| Barinthus Biotherapeutics PLC | 171.83M |
| TC BioPharm (Holdings) PLC | 3.421M |
| Adaptimmune Therapeutics PLC | 24.38M |
| Biodexa Pharmaceuticals Plc | 5.959M |
| Verona Pharma PLC | 224.99M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 145.74M |
| Total Liabilities (Quarterly) | 15.39M |